Health education and self-management support are key facilitators of health behaviours. Moxie is a mixed media, self-management, education and support program for Albertans living with cardiovascular-related chronic conditions. Moxie is built upon our previous work within the ACCESS study (2015-21, n=4761), a RCT that previously tested the Moxie intervention in Alberta. Results demonstrated that MOXIE reduced the rate of hospitalizations (notably for hypertension, angina, hyper/hypoglycemia, heart failure decompensation, and acute kidney complications) by 34% in a population of low-income seniors living with cardiovascular-related chronic conditions. However, before Moxie can be effectively implemented province-wide, another trial is necessary to determine whether benefits can be observed in a larger cohort of patients with cardiovascular-related chronic conditions recruited immediately after hospital discharge (n=9000). Furthermore, the effectiveness of the two components of the ACCESS trial intervention will be assessed individually: (a) The Moxie Program, a tailored health and disease education component developed by a user-experience-centric design process incorporating patients, behavioural scientists, disease specialists, health system administrators and marketing/advertising professionals; and (b) the facilitated relay of clinical information to healthcare providers (letters). The trial is designed as a 2x2 factorial pragmatic, individual-level randomized pragmatic trial of these different interventions. This would yield the following groups: 1. Moxie SMES Program 2. Facilitated Relay 3. Moxie SMES Program and Facilitated Relay 4. True control Self-management education and support (SMES) intervention: This includes weekly physical mailers sent directly to patients' homes throughout the study containing information about chronic conditions, medication use, diet, physical activity, smoking cessation, and self-management/wellness principles. These messages will be refined by the social impact creative design partner and reviewed by clinicians and patients to ensure clinical safety and appropriate tone. Weekly mailers will encourage participants to enroll and consent to participate in the digital program by scanning a QR code or accessing a website where they will sign up for their own personalized Moxie mobile health app, complete a digital consent form and opt-in for electronic delivery of Moxie messages. Facilitated relay intervention: Participants allocated to this intervention will receive letters by mail, one addressed to them, one to their primary care provider, and one to their pharmacist. The letters will not be sent to their primary care provider directly; rather, they will be sent to patients who will be encouraged to take them to their primary care provider and pharmacist should they decide to do so. We hope this will empower patients to start discussions with their healthcare providers. This also supports patient autonomy by enabling patients to decide whether they want to take them to their provider or not. If for whatever reason they do not feel that this is going to be beneficial or of interest, they are not required to do so. The letter would contain a note to the patient's healthcare provider stating that their patient is at-risk of cardiovascular disease and that evidence has shown that the pharmacotherapy is effective in improving outcomes for patients similar to the participant. The primary outcome is readmission for cardiovascular-specific ambulatory care-sensitive conditions (ACSC) based on the most responsible diagnosis listed in CIHI Discharge Abstract Database-(DAD), using established algorithms within 12 months from randomization. This outcome includes all repeat admissions in the study period as recorded in the health record. This outcome is a count variable. We will calculate and compare each intervention arm's mean number and distribution of hospitalizations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
9,000
Weekly mailer for the Moxie SMES Program.
One-time Facilitated Relay letter for the participant to share with their healthcare provider.
Hospital Readmissions
Readmission for cardiovascular-specific ambulatory care-sensitive conditions (ACSC) based on the most responsible diagnosis listed in CIHI-DAD (23). This outcome includes all repeat admissions in the study period as recorded in the AHS record that is sent to CIHI for inclusion in the Discharge Abstract Database (DAD). This outcome is a count variable. We will calculate and compare each intervention arm's mean number and distribution of hospitalizations.
Time frame: Within 12 months from randomization.
Overall Mortality
Death, for the purpose of this study, refers to all-cause mortality. The data source for this outcome is the Canadian Vital Statistics Database (CVSD).
Time frame: Within 12 months of randomization.
Cardiovascular-Kidney-Metabolic Death
The CVSD also records an ICD-10 code for the most responsible cause of death provided by the most responsible healthcare provider (death in an inpatient facility) or the coroner's office (death in the community). This code can be used to identify those who die of relevant causes if the assigned ICD-10 code is within the following ranges: cardiovascular (I00-I99), diabetes (E10-E14), or kidney-related (N00-N29).
Time frame: Within 12 months from randomization.
Cardioprotective Medication Initiation
Using data from Alberta's pharmacy dispensation repository, we will identify when a patient with an indicated condition starts a new medication that they were not previously taking in the prior 12 months. The combination of conditions and medications we will assess for include: Heart Failure= ACE/ARB/ARNI, SGLT2 inhibitors, MRA, Statins Chronic kidney disease with proteinuria (no diabetes)= ACE/ARB/ARNI, SGLT2 inhibitors, Statins Chronic kidney disease with proteinuria and diabetes= ACE/ARB/ARNI, SGLT2 inhibitors, Statins, Finerenone Chronic kidney disease without proteinuria= ACE/ARB/ARNI, Statins Coranary artery disease= ACE/ARB/ARNI, Statins Type 2 Diabetes= ACE/ARB/ARNI, SGLT2i or GLP1RA inhibitors, Statins
Time frame: Within 12 months from randomization.
Medication Adherence
Adherence to medications such as \\ACEi, ARBs, Statins, and other cardioprotective medications listed above will be assessed by calculating the proportion of days covered (calculated using the formula below) (sum of days covered in the period of interest (POI)) ÷ (number of days in the POI) × 100% (24). PDC of 80% or greater is considered adequate adherence. This data is sourced from the Pharmaceutical Information Network, which records information (date, drug name, DIN, strength, quantity, duration) for all dispensed prescriptions from outpatient pharmacies in Alberta.
Time frame: Within 12 months from randomization.
Primary Care and Specialty Utilization
Primary care and specialist visits are captured in the Physician Claims Database. Each encounter will be counted as one visit. This outcome is analysed as a count variable. We will calculate and compare the mean number and distribution of primary and specialist care visits.
Time frame: Within 12 months from randomization.
Healthcare System Costs
We will include costs for hospitalization and ED visits, physician claims (specialist and primary care physician visit and procedure billing costs), prescription medications, nonphysician ambulatory costs (day medicine and day surgery clinics), and outpatient diagnostic imaging and laboratory costs. The total costs will be calculated as the sum of these costs. Alberta Health uses Canadian Institute of Health Information case-mix grouper methods to estimate hospital costs and ambulatory-case costing methods to estimate emergency department costs. Physician claims will be based on the amount paid by Alberta Health. The cost of medications will be estimated by combining a database containing a comprehensive list of medications dispensed to all Alberta residents with a price list from Alberta Blue Cross, including dispensing fee. Diagnostic imaging and laboratory costs will be based on estimates provided by Alberta Health.
Time frame: Within 12 months from randomization.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.